Analyst Ratings For Oncolytics Biotech (TSE:ONC)
Today, BMO Capital Markets raised its price target on Oncolytics Biotech (TSE:ONC) to C$1.50 per share.
There are 2 buy ratings on the stock.
The current consensus rating on Oncolytics Biotech (TSE:ONC) is Buy (Score: 3.00) with a consensus target price of C$1.50 per share, a potential .
Some recent analyst ratings include
About Oncolytics Biotech (TSE:ONC)
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Recent Trading Activity for Oncolytics Biotech (TSE:ONC)
Shares of Oncolytics Biotech closed the previous trading session at 1.10 up +0.10 10.00% with 1,077,808 shares trading hands.